Qing-Kai-Ling oral liquid alleviates non-alcoholic fatty liver disease via remodeling gut microbiota and activating AMPK/ACC1 axis
These findings established QKL as a microbiota-modulating therapeutic agent for NAFLD through SCFA-AMPK/ACC1 axis activation, providing a foundation for developing QKL-based treatments.
Authors
- Xiaoqin Zhou
- Jingyun Wu
- Biyan Pan
- Fenglian Chen (ORCID: https://orcid.org/0000-0002-8218-1348)
- Zihao Chen (ORCID: https://orcid.org/0000-0002-9349-0349)
- Pei Li (ORCID: https://orcid.org/0000-0001-5509-7848)
- Qiuyun Wang (ORCID: https://orcid.org/0000-0003-1492-8857)
- Hong‐Ying Chen (ORCID: https://orcid.org/0000-0002-8245-3999)
- Zhiyong Xie (ORCID: https://orcid.org/0000-0001-8578-3275)
- Kaiwei Cai
- Qiongfeng Liao
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Sun Yat-sen University (CN)
- Guangdong Pharmaceutical University (CN)
- State Administration of Traditional Chinese Medicine of the People's Republic of China (CN)
- Guangzhou Experimental Station (CN)
Publication Details
- Journal
- Chinese Medicine
- Published
- 2025-10-19
- DOI
- https://doi.org/10.1186/s13020-025-01237-4
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Basic and Applied Basic Research Foundation of Guangdong Province